Resolution of malignant cutaneous lesions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma

Category Primary study
JournalJournal of the American Academy of Dermatology
Year 2012
This article has no abstract
Epistemonikos ID: d1f2b39b6fa4ad029bc9aea71296a0d380577da6
First added on: Feb 04, 2025